Molecular classifiers have been developed to categorize AML patients into risk-specific subgroups, including cytogenetically normal AML (CN-AML), core-binding factor AML (CBF-AML), and subgroups defined by specific mutations like FLT3-ITD or IDH mutations (9–13). This evidence concerns the gene IDH2 and acute myeloid leukemia.